Token economy, pimozide and chronic schizophrenia.
Response to a token economy was assessed in male chronic schizophrenic in-patients who were given, in a double-blind cross-over trial, pimozide (up to 20 mg daily) or chlorpromazine )up to 1,000 mg daily), each for three months. After six months there was little change in the patients' mental state, but general ward behaviour and token-rewarded "target"  behaviours improved significantly. There were no statistically significant between-drug differences, but the trend was that general ward behaviour, but not token-rewarded behaviour, improved more on pimozide. The patients who showed initiative and cooperated best with staff were those whose token-rewarded behaviour was most satisfactory.
D001521:Behavior Therapy; D002746:Chlorpromazine / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006778:Hospitals, Psychiatric; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010868:Pimozide / Q000627:therapeutic use*; D012201:Reward; D012559:Schizophrenia / Q000188:drug therapy*; D014040:Token Economy
D010868:Pimozide; D002746:Chlorpromazine